FT1
Phase 2Small molecule
FT1 is one of 11 small molecule programs targeting Short Bowel Syndrome. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Short Bowel Syndrome
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Victoza
Novo NordiskApproved
Glepaglutide
Zealand PharmaPhase 3
Apraglutide
VVectivBio AG
Phase 3
PJ009
CChongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
Celexa
AbbViePreclinical
Mytesi
NNapo Pharmaceuticals, Inc.
Phase 1
Genotropin
EMD SeronoPreclinical
Glutamine
SanofiPreclinical
FT1
CChongqing Peg-Bio Biopharm Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FT1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details